For the third quarter of fiscal year ending March 2026, net sales were 173,472 million yen (1.3% increase YoY), operating income was 31,826 million yen (11.0% decrease YoY), and net income attributable to owners of parent was 25,565 million yen (7.5% decrease YoY).<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4403","jir_company_name":"Nissin Chemical Industry Co., Ltd.","jir_importance":"\u2605\u2605\u2605\u2605\u2606","jir_publication_date":"2026-02-13","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/02\/4403-20260213-03.pdf","jir_short_summary":"For the third quarter of fiscal year ending March 2026, net sales were 173,472 million yen (1.3% increase YoY), operating income was 31,826 million yen (11.0% decrease YoY), and net income attributable to owners of parent was 25,565 million yen (7.5% decrease YoY).","jir_summary":"### Overview of Business Results\nFor the cumulative third quarter period of fiscal year ending March 2026 (April 1, 2025 to December 31, 2025), amid ongoing uncertainties in the global economy, net sales amounted to 173,472 million yen (1.3% increase YoY). Meanwhile, operating income declined to 31,826 million yen (11.0% decrease YoY), ordinary income was 34,518 million yen (8.2% decrease YoY), and net income attributable to owners of parent decreased to 25,565 million yen (7.5% decrease YoY). By segment, the Functional Chemicals division posted net sales of 106,969 million yen (6.6% decrease YoY) and operating income of 20,225 million yen (17.9% decrease YoY). The Pharmaceuticals, Medical, and Healthcare division recorded net sales of 36,455 million yen (0.1% decrease YoY) and operating income of 10,686 million yen (8.8% decrease YoY). The Chemical Drugs division achieved net sales of 29,552 million yen (50.1% increase YoY) and operating income of 2,845 million yen (83.0% increase YoY).\n\n### Financial Position, Dividends, and Share Buyback\nAt the end of the third quarter, total assets stood at 375,022 million yen, an increase of 17,826 million yen from the previous fiscal year-end, and net assets were 283,510 million yen, up 3,960 million yen. The number of treasury shares increased to 8,408,008 shares. The annual dividend forecast for fiscal year ending March 2026 was raised to 61.00 yen (compared to 45.00 yen last fiscal year). Additionally, at the Board of Directors meeting on February 13, 2026, a resolution was passed to repurchase treasury shares (up to 1,800,000 shares, 5,000,000,000 yen, from February 16 to March 31, 2026) to improve capital efficiency and strengthen shareholder returns.","jir_financial_highlights":"Net Sales: 173,472 million yen (1.3% increase YoY)\nOperating Income: 31,826 million yen (11.0% decrease YoY)\nOrdinary Income: 34,518 million yen (8.2% decrease YoY)\nNet Income Attributable to Owners of Parent: 25,565 million yen (7.5% decrease YoY)\nTotal Assets: 375,022 million yen (Increase of 17,826 million yen from previous fiscal year-end)\nNet Assets: 283,510 million yen (Increase of 3,960 million yen from previous fiscal year-end)\nNumber of Treasury Shares: 8,408,008 shares (Increased from 2,991,799 shares in the same period last year)\nAnnual Dividend (Forecast): 61.00 yen (Increase from 45.00 yen last fiscal year)","jir_category":"","jir_hashtags":"#NissinChemicalIndustry, #FinancialSummary, #JapaneseStocks","jir_key_figures":"Net Sales: 173,472 million yen (1.3% increase YoY)\nOperating Income: 31,826 million yen (11.0% decrease YoY)\nNet Income Attributable to Owners of Parent: 25,565 million yen (7.5% decrease YoY)","jir_meta_title":"Nissin Chemical Industry Co., Ltd. Financial Summary for Q3 Fiscal Year Ending March 2026: Net Sales of 173,472 Million Yen (1.3% Increase YoY)","jir_meta_description":"Financial summary of Nissin Chemical Industry Co., Ltd. for the third quarter of fiscal year ending March 2026. Net sales were 173,472 million yen (1.3% increase YoY), operating income 31,826 million yen (11.0% decrease YoY), and net income 25,565 million yen (7.5% decrease YoY). Treasury stock repurchase was also approved.","jir_og_title":"Nissin Chemical Industry Co., Ltd. Announces Financial Summary for Q3 Fiscal Year Ending March 2026","jir_og_description":"Net sales rose 1.3% YoY to 173,472 million yen. Operating income and net income declined. Latest financial information including approval of treasury stock repurchase.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[{\"jir_chart_id\": \"revenue_trend\", \"jir_chart_type\": \"bar\", \"jir_chart_title\": \"Net Sales Trend (Cumulative Q3)\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"bar\\\",\\\"data\\\":{\\\"labels\\\":[\\\"Q3 Fiscal Year Ending March 2025\\\",\\\"Q3 Fiscal Year Ending March 2026\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Net Sales (Million Yen)\\\",\\\"data\\\":[171170,173472],\\\"backgroundColor\\\":\\\"#4e79a7\\\"}]},\\\"options\\\":{\\\"scales\\\":{\\\"y\\\":{\\\"beginAtZero\\\":true}}}}\"}, {\"jir_chart_id\": \"operating_profit_trend\", \"jir_chart_type\": \"bar\", \"jir_chart_title\": \"Operating Income Trend (Cumulative Q3)\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"bar\\\",\\\"data\\\":{\\\"labels\\\":[\\\"Q3 Fiscal Year Ending March 2025\\\",\\\"Q3 Fiscal Year Ending March 2026\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Operating Income (Million Yen)\\\",\\\"data\\\":[35759,31826],\\\"backgroundColor\\\":\\\"#f28e2b\\\"}]},\\\"options\\\":{\\\"scales\\\":{\\\"y\\\":{\\\"beginAtZero\\\":true}}}}\"}, {\"jir_chart_id\": \"net_profit_trend\", \"jir_chart_type\": \"bar\", \"jir_chart_title\": \"Net Income Attributable to Owners of Parent Trend (Quarterly)\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"bar\\\",\\\"data\\\":{\\\"labels\\\":[\\\"Q3 Fiscal Year Ending March 2025\\\",\\\"Q3 Fiscal Year Ending March 2026\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Net Income (Million Yen)\\\",\\\"data\\\":[27627,25565],\\\"backgroundColor\\\":\\\"#e15759\\\"}]},\\\"options\\\":{\\\"scales\\\":{\\\"y\\\":{\\\"beginAtZero\\\":true}}}}\"}, {\"jir_chart_id\": \"segment_revenue_breakdown\", \"jir_chart_type\": \"pie\", \"jir_chart_title\": \"Segment Composition of Net Sales for Q3 Fiscal Year Ending March 2026\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"pie\\\",\\\"data\\\":{\\\"labels\\\":[\\\"Functional Chemicals Business\\\",\\\"Pharmaceuticals, Medical & Healthcare Business\\\",\\\"Chemical Drugs Business\\\",\\\"Others\\\"],\\\"datasets\\\":[{\\\"data\\\":[106969,36455,29552,495],\\\"backgroundColor\\\":[\\\"#4e79a7\\\",\\\"#f28e2b\\\",\\\"#e15759\\\",\\\"#76b7b2\\\"]}]}}\"}, {\"jir_chart_id\": \"segment_operating_profit_breakdown\", \"jir_chart_type\": \"pie\", \"jir_chart_title\": \"Segment Composition of Operating Income for Q3 Fiscal Year Ending March 2026\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"pie\\\",\\\"data\\\":{\\\"labels\\\":[\\\"Functional Chemicals Business\\\",\\\"Pharmaceuticals, Medical & Healthcare Business\\\",\\\"Chemical Drugs Business\\\",\\\"Others\\\"],\\\"datasets\\\":[{\\\"data\\\":[20225,10686,2845,378],\\\"backgroundColor\\\":[\\\"#4e79a7\\\",\\\"#f28e2b\\\",\\\"#e15759\\\",\\\"#76b7b2\\\"]}]}}\"}]","ir_related_company":7684,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"financial_summary","footnotes":""},"sector":[],"importance":[],"class_list":["post-29058","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n